These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 36964217)

  • 1. Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types.
    Sasaki K; Takahashi S; Ouchi K; Otsuki Y; Wakayama S; Ishioka C
    Sci Rep; 2023 Mar; 13(1):4868. PubMed ID: 36964217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations.
    Meng X; Yang S; Li Y; Li Y; Devor EJ; Bi J; Wang X; Umesalma S; Quelle DE; Thiel WH; Thiel KW; Leslie KK
    Dis Markers; 2018; 2018():3810108. PubMed ID: 30647797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
    Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
    J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant p53: it's not all one and the same.
    Kennedy MC; Lowe SW
    Cell Death Differ; 2022 May; 29(5):983-987. PubMed ID: 35361963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.
    Kang HJ; Chun SM; Kim KR; Sohn I; Sung CO
    PLoS One; 2013; 8(8):e72609. PubMed ID: 23967324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells.
    Nakazawa S; Sakata KI; Liang S; Yoshikawa K; Iizasa H; Tada M; Hamada JI; Kashiwazaki H; Kitagawa Y; Yamazaki Y
    Biomed Res; 2019; 40(1):37-49. PubMed ID: 30787262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 gain-of-function mutation promotes inflammation in glioblastoma.
    Ham SW; Jeon HY; Jin X; Kim EJ; Kim JK; Shin YJ; Lee Y; Kim SH; Lee SY; Seo S; Park MG; Kim HM; Nam DH; Kim H
    Cell Death Differ; 2019 Mar; 26(3):409-425. PubMed ID: 29786075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant p53 and mTOR/PKM2 regulation in cancer cells.
    Dando I; Cordani M; Donadelli M
    IUBMB Life; 2016 Sep; 68(9):722-6. PubMed ID: 27385486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.
    Chapman L; Ledet EM; Barata PC; Cotogno P; Manogue C; Moses M; Christensen BR; Steinwald P; Ranasinghe L; Layton JL; Lewis BE; Sartor O
    Clin Genitourin Cancer; 2020 Apr; 18(2):148-154. PubMed ID: 31822380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
    Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA
    Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 Gain-of-Function Mutation is a Poor Prognostic Factor in High-Methylated Metastatic Colorectal Cancer.
    Wakayama S; Ouchi K; Takahashi S; Yamada Y; Komatsu Y; Shimada K; Yamaguchi T; Shirota H; Takahashi M; Ishioka C
    Clin Colorectal Cancer; 2023 Sep; 22(3):327-338. PubMed ID: 37355363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [TP53 mutations and molecular epidemiology].
    Otsuka K; Ishioka C
    Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
    Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
    Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biallelic TP53 gain of function mutations in rapidly progressing solid tumors.
    Sande CM; Chang B; Monga V; Bossler AD; Ma D
    Cancer Genet; 2018 Apr; 222-223():20-24. PubMed ID: 29666004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 mutations, expression and interaction networks in human cancers.
    Wang X; Sun Q
    Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53.
    Huang Y; Jiao Z; Fu Y; Hou Y; Sun J; Hu F; Yu S; Gong K; Liu Y; Zhao G
    Eur J Med Chem; 2024 Feb; 265():116121. PubMed ID: 38194777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity.
    Xu J; Wang J; Hu Y; Qian J; Xu B; Chen H; Zou W; Fang JY
    Cell Death Dis; 2014 Mar; 5(3):e1108. PubMed ID: 24603336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-324-5p-CUEDC2 Axis Mediates Gain-of-Function Mutant p53-Driven Cancer Stemness.
    Ghatak D; Datta A; Roychowdhury T; Chattopadhyay S; Roychoudhury S
    Mol Cancer Res; 2021 Oct; 19(10):1635-1650. PubMed ID: 34257080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diverse and cancer type‑specific roles of the p53 R248Q gain‑of‑function mutation in cancer migration and invasiveness.
    Olszewski MB; Pruszko M; Snaar-Jagalska E; Zylicz A; Zylicz M
    Int J Oncol; 2019 Apr; 54(4):1168-1182. PubMed ID: 30968154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.